EMERGENT BIOSOLUTIONS INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
EMERGENT BIOSOLUTIONS INC. (EBS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $1.30 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2024-08-07
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2024-06-30 was $1.30M, a 116.67% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2024-03-31 was $600.00K, a 14.29% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-06-30 was $600.00K, a 25.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2023-03-31 was $700.00K, a 97.67% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $2.60M, a 92.12% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $33.00M, a 38.66% increase from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2021 was $23.80M, a 750.00% increase from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2020 was $2.80M, a 95.10% decline from fiscal 2019.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-07 | $1.90M derived: sum of 2 quarters · filed 2024-08-07 | |||
| 2024-03-31 | $600.00K 10-Q · filed 2024-08-07 | ||||
| 2023-12-31 | $2.60M 10-K · filed 2024-03-08 | ||||
| 2023-06-30 | $600.00K 10-Q · filed 2024-08-07 | $600.00K 10-Q · filed 2023-08-09 | $2.50M derived: sum of 3 quarters · filed 2024-08-07 | $3.40M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $700.00K 10-Q · filed 2024-08-07 | $1.90M derived: sum of 2 quarters · filed 2024-08-07 | $2.80M derived: sum of 3 quarters · filed 2024-08-07 | $3.60M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2022-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $2.10M derived: sum of 2 quarters · filed 2024-03-08 | $2.90M derived: sum of 3 quarters · filed 2024-03-08 | $33.00M 10-K · filed 2024-03-08 | |
| 2022-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.70M derived: sum of 2 quarters · filed 2022-11-09 | $31.80M 10-Q · filed 2022-11-09 | $32.60M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $30.90M 10-Q · filed 2022-08-02 | $31.70M derived: sum of 3 quarters · filed 2024-03-08 | $33.00M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-03-31 | $30.10M 10-Q · filed 2022-04-29 | $30.90M derived: sum of 2 quarters · filed 2024-03-08 | $32.20M derived: sum of 3 quarters · filed 2024-03-08 | $32.70M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2021-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $2.10M derived: sum of 2 quarters · filed 2024-03-08 | $2.60M derived: sum of 3 quarters · filed 2024-03-08 | $23.80M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.80M derived: sum of 2 quarters · filed 2021-11-05 | $23.00M 10-Q · filed 2021-11-05 | $23.60M derived: sum of 4 quarters · filed 2023-12-11 | |
| 2021-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $21.70M 10-Q · filed 2021-07-30 | $22.30M derived: sum of 3 quarters · filed 2023-12-11 | $23.40M derived: sum of 4 quarters · filed 2023-12-11 | |
| 2021-03-31 | $21.20M 10-Q · filed 2021-04-30 | $21.80M derived: sum of 2 quarters · filed 2023-12-11 | $22.90M derived: sum of 3 quarters · filed 2023-12-11 | $23.30M derived: sum of 4 quarters · filed 2023-12-11 | |
| 2020-12-31 | $600.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $1.70M derived: sum of 2 quarters · filed 2023-12-11 | $2.10M derived: sum of 3 quarters · filed 2023-12-11 | $2.80M 10-K/A · filed 2023-12-11 | |
| 2020-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.50M derived: sum of 2 quarters · filed 2020-11-06 | $2.20M 10-Q · filed 2020-11-06 | $45.60M derived: sum of 4 quarters · filed 2021-02-19 | |
| 2020-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $1.10M 10-Q · filed 2020-07-31 | $44.50M derived: sum of 3 quarters · filed 2021-02-19 | $46.20M derived: sum of 4 quarters · filed 2021-02-19 | |
| 2020-03-31 | $700.00K 10-Q · filed 2020-05-01 | $44.10M derived: sum of 2 quarters · filed 2021-02-19 | $45.80M derived: sum of 3 quarters · filed 2021-02-19 | $57.30M derived: sum of 4 quarters · filed 2021-02-19 | |
| 2019-12-31 | $43.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $45.10M derived: sum of 2 quarters · filed 2021-02-19 | $56.60M derived: sum of 3 quarters · filed 2021-02-19 | $57.10M 10-K · filed 2021-02-19 | $67.10M 10-K · filed 2020-02-25 |
| 2019-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $13.20M derived: sum of 2 quarters · filed 2019-11-07 | $13.70M 10-Q · filed 2019-11-07 | $14.87M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2019-06-30 | $11.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $12.00M 10-Q · filed 2019-08-02 | $13.17M derived: sum of 3 quarters · filed 2020-02-25 | $14.14M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2019-03-31 | $500.00K 10-Q · filed 2019-05-08 | $1.67M derived: sum of 2 quarters · filed 2020-02-25 | $2.64M derived: sum of 3 quarters · filed 2020-02-25 | $3.11M derived: sum of 4 quarters · filed 2020-02-25 | |
| 2018-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $2.14M derived: sum of 2 quarters · filed 2020-02-25 | $2.61M derived: sum of 3 quarters · filed 2020-02-25 | $3.40M 10-K · filed 2020-02-25 | $3.40K 10-K · filed 2019-02-22 |
| 2018-09-30 | $977.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $1.44M derived: sum of 2 quarters · filed 2018-11-02 | $2.23M 10-Q · filed 2018-11-02 | -$499.10K derived: sum of 4 quarters · filed 2019-02-22 | |
| 2018-06-30 | $464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $1.26M 10-Q · filed 2018-08-03 | -$1.48M derived: sum of 3 quarters · filed 2019-02-22 | -$1.14M derived: sum of 4 quarters · filed 2019-02-22 | |
| 2018-03-31 | $793.00K 10-Q · filed 2018-05-04 | -$1.94M derived: sum of 2 quarters · filed 2019-02-22 | -$1.60M derived: sum of 3 quarters · filed 2019-02-22 | -$764.10K derived: sum of 4 quarters · filed 2019-02-22 | |
| 2017-12-31 | -$2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$2.39M derived: sum of 2 quarters · filed 2019-02-22 | -$1.56M derived: sum of 3 quarters · filed 2019-02-22 | $10.90K 10-K · filed 2019-02-22 | $10.94M 10-K · filed 2018-02-23 |
| 2017-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $1.18M derived: sum of 2 quarters · filed 2017-11-03 | $2.74M 10-Q · filed 2017-11-03 | $2.89M derived: sum of 4 quarters · filed 2018-02-23 | |
| 2017-06-30 | $837.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $2.40M 10-Q · filed 2017-08-04 | $2.55M derived: sum of 3 quarters · filed 2018-02-23 | $2.55M derived: sum of 4 quarters · filed 2018-02-23 | |
| 2017-03-31 | $1.57M 10-Q · filed 2017-05-05 | $1.72M derived: sum of 2 quarters · filed 2018-02-23 | $1.71M derived: sum of 3 quarters · filed 2018-02-23 | $1.93M derived: sum of 4 quarters · filed 2018-02-23 | |
| 2016-12-31 | $149.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $142.00K derived: sum of 2 quarters · filed 2018-02-23 | $361.00K derived: sum of 3 quarters · filed 2018-02-23 | $1.11M 10-K · filed 2018-02-23 | |
| 2016-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $212.00K derived: sum of 2 quarters · filed 2016-11-09 | $964.00K 10-Q · filed 2016-11-09 | $340.00K derived: sum of 4 quarters · filed 2017-02-28 | |
| 2016-06-30 | $219.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $971.00K 10-Q · filed 2016-08-05 | $347.00K derived: sum of 3 quarters · filed 2017-02-28 | $772.00K derived: sum of 4 quarters · filed 2017-02-28 | |
| 2016-03-31 | $752.00K 10-Q · filed 2016-05-06 | $128.00K derived: sum of 2 quarters · filed 2017-02-28 | $553.00K derived: sum of 3 quarters · filed 2017-02-28 | $4.79M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-12-31 | -$624.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$199.00K derived: sum of 2 quarters · filed 2017-02-28 | $4.04M derived: sum of 3 quarters · filed 2017-02-28 | $4.80M 10-K · filed 2017-02-28 | $5.69M 10-K · filed 2016-02-29 |
| 2015-09-30 | $425.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $4.67M derived: sum of 2 quarters · filed 2015-11-06 | $5.43M 10-Q · filed 2015-11-06 | $5.32M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2015-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $5.00M 10-Q · filed 2015-08-06 | $4.89M derived: sum of 3 quarters · filed 2016-02-29 | $5.56M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2015-03-31 | $762.00K 10-Q · filed 2015-05-08 | $650.00K derived: sum of 2 quarters · filed 2016-02-29 | $1.32M derived: sum of 3 quarters · filed 2016-02-29 | $1.85M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-12-31 | -$112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $560.00K derived: sum of 2 quarters · filed 2016-02-29 | $1.09M derived: sum of 3 quarters · filed 2016-02-29 | $1.58M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $1.20M derived: sum of 2 quarters · filed 2014-11-10 | $1.69M 10-Q · filed 2014-11-10 | $2.04M derived: sum of 4 quarters · filed 2015-03-09 | |
| 2014-06-30 | $532.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $1.02M 10-Q · filed 2014-08-08 | $1.37M derived: sum of 3 quarters · filed 2015-03-09 | ||
| 2014-03-31 | $487.00K 10-Q · filed 2014-05-12 | $835.00K derived: sum of 2 quarters · filed 2015-03-09 | |||
| 2013-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $348.00K 10-K · filed 2015-03-09 | |||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-08 | ||||
| 2012-12-31 | $1.75M 10-K · filed 2014-03-10 | ||||
| 2012-06-30 | -$1.75M 10-Q · filed 2012-08-03 | ||||
| 2011-12-31 | $10.00M 10-K · filed 2013-03-08 | -$10.00M 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |